PANDAS
10
3
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
20%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS
PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Characterization and Prospective Course
Intravenous Immunoglobulin for PANDAS
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS